Investments
AIQ Solutions Inc., Madison, Wisconsin, USA
AIQ Solutions provides an AI-powered software solution for the automated assessment of therapy response in patients with late-stage cancer. This significantly improves the individual selection of remaining therapy options in late-stage tumors and enhances prognostic evaluation.
Nuclide Therapeutics Ltd., London, UK
Nuclide Therapeutics develops radiopharmaceuticals targeting tumor stem cells which mediate resistance to chemo- or radiotherapy. The therapeutic principle is based on a tumor-agnostic mechanism hitherto not addressed.
WM Therapeutics AG, Heidelberg, Germany
WMT develops active ingredients with a unique novel mechanism of action, known as „translational trap,“ to date not exploited globally. The mechanism shows promise to treat viral infections, inflammatory diseases, and cancer.
immuneAdvice GmbH, Reutlingen, Germany
CD4-specific immune cell tracer (CD4 ICE-T) for non-invasive PET imaging of
tumor immune status for early detection of checkpoint inhibitor resistance.
For Prospective Investments
- You are a founder, researcher, or inventor of groundbreaking new technologies which you would like to develop and commercialize in the framework of an own company.
- You are looking for a financing partner understanding and valuing outstanding scientific achievements with potential to solve fundamental problems.
- You are seeking an interdisciplinary partnership at eye level which is not afraid of ambitious goals.